China Shineway Pharmaceutical Group Limited (C1S) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) has a cash flow conversion efficiency ratio of 0.024x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€160.69 Million ≈ $187.86 Million USD) by net assets (€6.64 Billion ≈ $7.76 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see China Shineway Pharmaceutical Group Limi stock valuation for the company's overall valuation and market capitalisation.
China Shineway Pharmaceutical Group Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
China Shineway Pharmaceutical Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their cash flow conversion efficiency. Explore C1S cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guoguang Electric Co Ltd Chengdu
SHG:688776
|
-0.019x |
|
Magic Software Enterprises Ltd
TA:MGIC
|
0.064x |
|
Zhejiang Fuchunjiang Environmental Thermoelectric Co Ltd
SHE:002479
|
0.031x |
|
Shinyoung Securities Co. Ltd.
KO:001720
|
-0.156x |
|
Jiangyin Haida Rubber and Plastic Co Ltd Class A
SHE:300320
|
0.016x |
|
Burelle SA
PA:BUR
|
0.141x |
|
Bowman Consulting Group Ltd
NASDAQ:BWMN
|
-0.031x |
|
MorningStar Partners, L.P.
NYSE:TXO
|
0.040x |
Annual Cash Flow Conversion Efficiency for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of China Shineway Pharmaceutical Group Limited from 2013 to 2025. View C1S live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €8.06 Billion ≈ $9.43 Billion |
€1.17 Billion ≈ $1.37 Billion |
0.145x | +12.71% |
| 2024-12-31 | €7.47 Billion ≈ $8.73 Billion |
€963.13 Million ≈ $1.13 Billion |
0.129x | -2.71% |
| 2023-12-31 | €7.03 Billion ≈ $8.22 Billion |
€932.63 Million ≈ $1.09 Billion |
0.133x | -23.75% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.174x | +45.92% |
| 2021-12-31 | €5.90 Billion ≈ $6.90 Billion |
€703.15 Million ≈ $822.06 Million |
0.119x | +8.11% |
| 2020-12-31 | €5.79 Billion ≈ $6.77 Billion |
€638.57 Million ≈ $746.55 Million |
0.110x | +73.01% |
| 2019-12-31 | €5.78 Billion ≈ $6.75 Billion |
€368.00 Million ≈ $430.23 Million |
0.064x | -31.04% |
| 2018-12-31 | €5.77 Billion ≈ $6.74 Billion |
€532.59 Million ≈ $622.65 Million |
0.092x | +9.59% |
| 2017-12-31 | €5.82 Billion ≈ $6.81 Billion |
€490.65 Million ≈ $573.62 Million |
0.084x | -35.34% |
| 2016-12-31 | €5.63 Billion ≈ $6.58 Billion |
€733.53 Million ≈ $857.57 Million |
0.130x | -7.29% |
| 2015-12-31 | €5.30 Billion ≈ $6.19 Billion |
€744.71 Million ≈ $870.64 Million |
0.141x | -11.01% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€773.16 Million ≈ $903.90 Million |
0.158x | +34.64% |
| 2013-12-31 | €4.43 Billion ≈ $5.18 Billion |
€519.89 Million ≈ $607.80 Million |
0.117x | -- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more